Stephan Bek
Impact in
- Immunology top 2%
- Psoriasis: Treatment and Pathogenesis
- IL-33, ST2, and ILC Pathways
- Immune Cell Function and Interaction
- Rheumatology top 2%
- Spondyloarthritis Studies and Treatments
Papers in
-
- Peroxisome Proliferator-Activated Receptors 1
-
- Natural Antidiabetic Agents Studies 2
- Co-authors
- Steve Lewitzky (1 shared paper)Arthur P. Bertolino (1 shared paper)Marco Londei (1 shared paper)Peter Higgins (1 shared paper)Brian G. Feagan (1 shared paper)Gervais Tougas (1 shared paper)Simon Travis (1 shared paper)Walter Reinisch (1 shared paper)
- Journals
- Gut (1 paper)Toxicology and Applied Pharmacology (1 paper)Biochemical and Biophysical Research Communications (1 paper)Journal of Cell Science (1 paper)Analytical Chemistry (1 paper)
- Partner nations
- GermanySwitzerlandUnited States
In The Last Decade
Stephan Bek
11 papers receiving 1.8k citations
Stephan Bek's Hit Papers
Peers
Comparison fields: 5 of 89
- Immunology 904
- Rheumatology 312
- Hematology 209
- Genetics 458
- Dermatology 129
Countries citing papers authored by Stephan Bek
This map shows the geographic impact of Stephan Bek's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Stephan Bek with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Stephan Bek more than expected).
Fields of papers citing papers by Stephan Bek
This network shows the impact of papers produced by Stephan Bek. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Stephan Bek. The network helps show where Stephan Bek may publish in the future.
Co-authors
The 25 scholars most cited alongside Stephan Bek, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: unexpected results of a randomised, double-blind placebo-controlled trial Hit paper breakdown → | 2012 | 1171 |
| 2 | 2009 | 233 | |
| 3 | 2008 | 94 | |
| 4 | 2016 | 83 | |
| 5 | 2017 | 74 | |
| 6 | 2002 | 73 | |
| 7 | 2003 | 61 | |
| 8 | 2005 | 38 | |
| 9 | 2014 | 8 | |
| 10 | 2019 | 4 | |
| 11 | Improvement in Signs and Symptoms of Active Ankylosing Spondylitis Following Treatment with Anti-Interleukin (IL)-17A Monoclonal Antibody Secukinumab Are Paralleled by Reductions in Acute Phase Markers and Inflammatory Markers S100A8 and A9 (Calgranulin A and B) | 2012 | 2 |
About Stephan Bek
Stephan Bek is a scholar working on Molecular Biology, Endocrinology, Diabetes and Metabolism, Pathology and Forensic Medicine, Clinical Biochemistry and Rheumatology, having authored 11 papers that have together received 1.8k indexed citations. Recurring topics across this work include Rheumatoid Arthritis Research and Therapies (2 papers), Advanced Glycation End Products research (2 papers), Natural Antidiabetic Agents Studies (2 papers), Alcohol Consumption and Health Effects (2 papers), Monoclonal and Polyclonal Antibodies Research (2 papers), Inflammatory Bowel Disease (2 papers), Peroxisome Proliferator-Activated Receptors (1 paper) and Advanced Proteomics Techniques and Applications (1 paper). The work is most often cited by research in Immunology (904 citations), Rheumatology (312 citations), Hematology (209 citations), Genetics (458 citations) and Dermatology (129 citations). Stephan Bek has collaborated with scholars based in Germany, Switzerland and United States. Frequent co-authors include Steve Lewitzky, Arthur P. Bertolino, Marco Londei, Peter Higgins, Brian G. Feagan, Gervais Tougas, Simon Travis, Walter Reinisch, Wolfgang Hueber and Marek Karczewski. Their work appears in journals such as Gut, Toxicology and Applied Pharmacology, Biochemical and Biophysical Research Communications, Journal of Cell Science and Analytical Chemistry.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.